Published in Hepatitis Weekly, February 9th, 2004
Two phase I clinical studies will examine the safety, dose tolerability, immunological and anti-viral activity of subcutaneous Actilon, first in healthy volunteers, and then in HCV positive patients. Coley expects to enroll 40 healthy volunteers and forty patients in these blinded, placebo controlled, dose-escalation studies. The timeline for completing phase I clinical studies of Actilon is the first half of 2004. Information gained in these studies will be used to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly